• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/9/21 5:00:42 PM ET
    $ORPH
    Computer Software: Prepackaged Software
    Technology
    Get the next $ORPH alert in real time by email
    SC 13G 1 tm215754d1_sc13g.htm SC 13G

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.  )*

     

    Orphazyme A/S

    (Name of Issuer)

     

    Ordinary Shares

    (Title of Class of Securities)

     

    687305102

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    o Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 687305102
     
      1 Name of Reporting Persons
    Coöperatieve Aescap Venture I U.A.
     
      2 Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,758,105
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,758,105
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,758,105
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    FI
               

    (1) Based upon 34,697,763 ordinary shares outstanding as of October 1, 2020, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) October 2, 2020.

     

    2

     

     

      1 Name of Reporting Persons
    Aescap Venture Management B.V.
     
      2 Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,758,105
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,758,105
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,758,105
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    FI
               

     

    (1) Based upon 34,697,763 ordinary shares outstanding as of October 1, 2020, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) October 2, 2020.

     

    3

     

     

      1 Name of Reporting Persons
    Patrick Johan Hendrik Krol
     
      2 Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,758,105
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,758,105
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,758,105
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    IN
               

     

    (1) Based upon 34,697,763 ordinary shares outstanding as of October 1, 2020, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) October 2, 2020.

     

    4

     

     

      1 Name of Reporting Persons
    Johan Gerhard Bosman
     
      2 Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,758,105
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,758,105
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,758,105
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    IN
               

     

    (1) Based upon 34,697,763 ordinary shares outstanding as of October 1, 2020, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) October 2, 2020.

     

    5

     

     

      1 Name of Reporting Persons
    Michiel Alexander de Haan
     
      2 Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,758,105
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,758,105
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,758,105
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    IN
               

     

    (1) Based upon 34,697,763 ordinary shares outstanding as of October 1, 2020, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) October 2, 2020.

     

    6

     

     

    Item 1.
      (a). Name of Issuer
    Orphazyme A/S (the “Issuer”)
      (b).

    Address of Issuer’s Principal Executive Offices:
    Ole Maaløes Vej 3, DK-2200

    Copenhagen N

    Denmark

     
    Item 2(a). Name of Person Filing
    Item 2(b). Address of Principal Business Office
    Item 2(c).

    Citizenship

     

    (i) Coöperatieve Aescap Venture I U.A. (Fund”)
    Barbara Strozzilaan 101
    1083 HN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    (ii) Aescap Venture Management B.V. (“Management”), as the manager of the Fund
    Barbara Strozzilaan 101
    1083 HN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    (iii) Patrick Johan Hendrik Krol (“Krol”), as a managing director of Management
    Barbara Strozzilaan 101
    1083 HN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    (iv) Johan Gerhard Bosman (“Bosman”), as a managing director of Management

    Barbara Strozzilaan 101
    1083 HN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    (v) Michiel Alexander de Haan (“de Haan”), as a managing director of Management

    Barbara Strozzilaan 101
    1083 HN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

    Item 2(d). Title of Class of Securities:
    Ordinary Shares (the “Shares”)
    Item 2(e). CUSIP Number:
    687305102
     
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
      This Item 3 is not applicable.

     

    7

     

     

    Item 4. Ownership.
      (a)

    Amount beneficially owned:

    As the manager of the Fund, any Shares held by the Fund may be deemed to be beneficially owned by Management. By virtue of their position as managers of Management, each of Krol, Bosman and de Haan may be deemed to beneficially own and have shared voting and dispositive power with respect to the Shares beneficially owned by Management

    As of the date of this report, the Fund held an aggregate of 1,758,105 Shares.

      (b)

    Percent of class:

    The Fund may be deemed the beneficial owner of approximately 5.1% of the Shares outstanding.
    Management may be deemed the beneficial owner of approximately 5.1% of the Shares outstanding.

    Each of Krol, Bosman and de Haan may be deemed the beneficial owner of approximately 5.1% of the Shares outstanding.

      (c)

    Number of shares as to which the Reporting person has:

    Fund:

        (i)

    Sole power to vote or to direct the vote:

    0

        (ii)

    Shared power to vote or to direct the vote:

    1,758,105

        (iii)

    Sole power to dispose or to direct the disposition of:

    0

        (iv)

    Shared power to dispose or to direct the disposition of:

    1,758,105

        Management:
        (i)

    Sole power to vote or to direct the vote:

    0

        (ii)

    Shared power to vote or to direct the vote:

    1,758,105

        (iii)

    Sole power to dispose or to direct the disposition of:

    0

        (iv)

    Shared power to dispose or to direct the disposition of:

    1,758,105

        Krol:
        (i)

    Sole power to vote or to direct the vote:

    0

        (ii)

    Shared power to vote or to direct the vote:

    1,758,105

        (iii)

    Sole power to dispose or to direct the disposition of:

    0

        (iv)

    Shared power to dispose or to direct the disposition of:

    1,758,105

        Bosman:
        (i)

    Sole power to vote or to direct the vote:

    0

        (ii)

    Shared power to vote or to direct the vote:

    1,758,105

        (iii)

    Sole power to dispose or to direct the disposition of:

    0

        (iv)

    Shared power to dispose or to direct the disposition of:

    1,758,105

     

        de Haan:
        (i)

    Sole power to vote or to direct the vote:

    0

        (ii)

    Shared power to vote or to direct the vote:

    1,758,105

        (iii)

    Sole power to dispose or to direct the disposition of:

    0

        (iv)

    Shared power to dispose or to direct the disposition of:

    1,758,105

     

    8

     

     

    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:    
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
    This Item 6 is not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
    This Item 7 is not applicable.
     
    Item 8. Identification and Classification of Members of the Group.
       
    This Item 8 is not applicable.
     
    Item 9. Notice of Dissolution of Group.
       
    This Item 9 is not applicable.

     

    Item 10. Certification.
       
    This Item 10 is not applicable.

     

    9

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 9, 2021

     

      Coöperatieve Aescap Venture I U.A.
       
      By: /s/Patrick Krol | /s/Hans Bosman
        Name: Aescap Venture Management B.V.,
    represented by Patrick Krol and Hans Bosman
        Title: Managing Directors

     

      Aescap Venture Management B.V.
       
      By: /s/Patrick Krol | /s/Hans Bosman
        Name: Patrick Krol and Hans Bosman
        Title: Managing Directors

     

     

      Patrick Johan Hendrik Krol
       
      By: /s/Patrick Johan Hendrik Krol

     

     

      Johan Gerhard Bosman
       
      By: /s/Johan Gerhard Bosman

     

     

      Michiel Alexander de Haan
       
      By: /s/Michiel Alexander de Haan

     

    10

     

    Get the next $ORPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

      Notes CytRx's Core Assets Are Unaffected by European Medicines Agency's Assessment of Arimoclomol Highlights Positive Developments Regarding Company's Core Assets, Including Aldoxorubicin CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medicinal Products for Human Use ("CHMP") of the

      2/24/22 8:00:00 AM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

      Orphazyme Intends to Request a Type C Meeting in Q2 2022 Orphazyme Plans to Resubmit the NDA During H2 2022, Subject to FDA Discussions European Medicines Agency Opinion Expected in Q1 2022 CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type

      2/14/22 8:00:00 AM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • CytRx Comments on Quarterly Results and Recent Strategic Initiatives

      CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the quarter ended September 30, 2021. In addition, CytRx recapped corporate developments as well as matters pertaining to its agreements with ImmunityBio, Inc. (NASDAQ:IBRX) ("ImmunityBio") and Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme"). The Company's 10-Q was filed today. Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, commented: "We continued to prudently manage our capital and streamlined operations while awaiting potential developments with

      11/12/21 8:00:00 AM ET
      $IBRX
      $ORPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology

    $ORPH
    Leadership Updates

    Live Leadership Updates

    See more
    • CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

      LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021. This appointment comes as Orphazyme awaits potential Food and Drug Administration ("FDA") approval of arimoclomol for the treatment of Niemann-Pick disease Type C ("NPC"). CytRx has an agreement with Orphazyme that can yield potential milestone payments and future single and doubl

      3/4/21 8:00:00 AM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology

    $ORPH
    SEC Filings

    See more
    • SEC Form 6-K filed by Orphazyme A/S

      6-K - Orphazyme A/S (0001764791) (Filer)

      6/29/22 4:10:00 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 20-F filed by Orphazyme A/S

      20-F - Orphazyme A/S (0001764791) (Filer)

      6/28/22 4:36:50 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 6-K filed by Orphazyme A/S

      6-K - Orphazyme A/S (0001764791) (Filer)

      6/21/22 4:18:01 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology

    $ORPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Orphazyme A/S (Amendment)

      SC 13G/A - Orphazyme A/S (0001764791) (Subject)

      2/3/22 4:16:01 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed

      SC 13G - Orphazyme A/S (0001764791) (Subject)

      2/11/21 4:16:23 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed

      SC 13G - Orphazyme A/S (0001764791) (Subject)

      2/9/21 5:00:42 PM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology

    $ORPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Orphazyme downgraded by Guggenheim

      Guggenheim downgraded Orphazyme from Buy to Sell

      6/21/21 8:05:16 AM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology
    • Orphazyme downgraded by BofA Securities with a new price target

      BofA Securities downgraded Orphazyme from Neutral to Underperform and set a new price target of $5.00 from $13.00 previously

      3/30/21 6:39:30 AM ET
      $ORPH
      Computer Software: Prepackaged Software
      Technology